Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icaritin vs Cinobufotalin in Advanced HCC
NCT03236636Phase 3Unknown
- Start
- Sep 2017
- Primary completion
- Dec 2022
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Icaritin in hepatocellular carcinoma (HCC) (2 arms). Primary endpoint: Overall Survival. Status: unknown.
02
Drugs
Icaritin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03236636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03236636.